Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Chronic heart failure: an overview of conventional treatment versus novel approaches

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 628–638 (2005)Cite this article

Abstract

Chronic heart failure (CHF) is a leading cause of hospitalization and is associated with a poor prognosis, although in the past decade substantial progress has been made in understanding the pathophysiology and therapy of CHF with reduced left ventricular (LV) ejection fraction. Use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor antagonists either individually or in combination, certain β-receptor blockers, and judicious use of aldosterone antagonists, has reduced hospital admission rates and mortality from CHF with reduced LV ejection fraction. More clinical trials are needed, however, particularly in patients with CHF and preserved LV ejection fraction. In patients who remain symptomatic despite medical therapy, and who have long QRS intervals (>0.12 s) and markedly reduced LV ejection fraction, the value of cardiac resynchronization therapy with a biventricular pacemaker has now been demonstrated. Yet, morbidity and mortality remain high, indicating a major need for further improvement. Novel therapies include medical management with statins, vasopressin antagonists, erythropoietin, oxypurinol and levosimendan, which improve vascular and myocardial function and reduce fluid overload, in addition to surgical approaches, which reduce LV remodeling. These routes might not, however, suffice in patients with CHF and LV dysfunction. Prevention of apoptosis and particularly regeneration of cardiac muscle would represent a shift of the current paradigm. Stem-cell-based therapies are rapidly evolving, and while basic science is needed to optimize these strategies, medium-sized clinical studies could help to verify the beneficial effects on LV function. In this review, we discuss current treatment methods and new strategies to improve treatment of CHF.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Summary of several large clinical trials of medical and device therapies in patients with systolic and diastolic chronic heart failure.
Figure 2: Summary of novel therapeutic targets currently under investigation in heart failure.
Figure 3: Proposed mechanisms of beneficial, cholesterol-independent effects of statin therapy in heart failure.

Similar content being viewed by others

References

  1. Garg R and Yusuf S (1995) Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273: 1450–1456

    Article  CAS  Google Scholar 

  2. Granger CB et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772–776

    Article  CAS  Google Scholar 

  3. Cohn JN et al. (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667–1675

    Article  CAS  Google Scholar 

  4. Gheorghiade M et al. (2003) β-blockers in chronic heart failure. Circulation 107: 1570–1575

    Article  Google Scholar 

  5. Bristow MR (2000) β-adrenergic receptor blockade in chronic heart failure. Circulation 101: 558–569

    Article  CAS  Google Scholar 

  6. The Beta-Blocker Evaluation of Survival Trial Investigators (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344: 1659–1667

  7. Bristow MR et al. (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94: 2807–2816

    Article  CAS  Google Scholar 

  8. Wikstrand J et al.; Merit-HF Study Group (2002) Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 40: 491–498

    Article  CAS  Google Scholar 

  9. Simon T et al. (2003) Bisoprolol dose–response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II). Eur Heart J 24: 552–559

    Article  CAS  Google Scholar 

  10. Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717

    Article  CAS  Google Scholar 

  11. Juurlink DN (2004) et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543–551

    Article  CAS  Google Scholar 

  12. McMurray JJ et al. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767–771

    Article  CAS  Google Scholar 

  13. Pfeffer MA et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893–1906

    Article  CAS  Google Scholar 

  14. Katada J et al. (2005) Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 111: 2157–2164

    Article  CAS  Google Scholar 

  15. Khand AU et al. (2003) Khand AU Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42: 1944–1951

    Article  CAS  Google Scholar 

  16. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533

  17. Rathore SS et al. (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871–878

    Article  CAS  Google Scholar 

  18. Rathore SS et al. (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347: 1403–1411

    Article  CAS  Google Scholar 

  19. Taylor AL et al.; African–American Heart Failure Trial Investigators (2004) Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351: 2049–2057

    Article  CAS  Google Scholar 

  20. Carson P et al. (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5: 178–187

    Article  CAS  Google Scholar 

  21. Redfield MM et al. (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194–202

    Article  Google Scholar 

  22. Yusuf S et al. (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777–781

    Article  CAS  Google Scholar 

  23. Flather MD et al. (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215–225

    Article  CAS  Google Scholar 

  24. Pina IL et al. (2003) Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 107: 1210–1225

    Article  Google Scholar 

  25. Bristow MR et al. for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140–2150

    Article  CAS  Google Scholar 

  26. Cleland JG et al. for the Cardiac Resynchronization—Heart Failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352: 1539–1549

    Article  CAS  Google Scholar 

  27. Bardy GH et al. (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352: 225–237

    Article  CAS  Google Scholar 

  28. Rose EA et al. for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group (2001) Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345: 1435–1443

    Article  CAS  Google Scholar 

  29. Bauersachs J et al. (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982–985

    Article  CAS  Google Scholar 

  30. Landmesser U et al. (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, LV function and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110: 1933–1939

    Article  CAS  Google Scholar 

  31. Node K et al. (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839–843

    Article  CAS  Google Scholar 

  32. Landmesser U et al. (2005) Simvastatin versus Ezetimibe: Pleiotropic and lipid lowering effects on endothelial function in humans. Circulation 111: 2356–2363

    Article  CAS  Google Scholar 

  33. Horwich TB et al. (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardio 43: 642–648

    Article  CAS  Google Scholar 

  34. Rauchhaus M et al. (2003) The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 42: 1933–1940

    Article  CAS  Google Scholar 

  35. Francis GS et al. (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82: 1724–1729

    Article  CAS  Google Scholar 

  36. Gheoghiade M et al. (2003) Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure. Circulation 107: 2690–2696

    Article  Google Scholar 

  37. Gheorghiade M et al. (2004) Effects of tolvaptan vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291: 1963–1971

    Article  CAS  Google Scholar 

  38. Udelson JE et al. (2001) Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104: 2417–2423

    Article  CAS  Google Scholar 

  39. Russell SD et al. (2003) Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J 145: 179–186

    Article  CAS  Google Scholar 

  40. Gheorghiade M et al. (2005) Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 11: 260–269

    Article  CAS  Google Scholar 

  41. Hare JM et al. (2005) NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115: 509–517

    Article  CAS  Google Scholar 

  42. Landmesser U et al. (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106: 3073–3078

    Article  CAS  Google Scholar 

  43. Cappola TP et al. (2001) Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104: 2407–2411

    Article  CAS  Google Scholar 

  44. Doehner W et al. (2002) Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105: 2619–2624

    Article  CAS  Google Scholar 

  45. Engberding N et al. (2004) Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110: 2175–2179

    Article  CAS  Google Scholar 

  46. Stull LB et al. (2004) Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 95: 1005–1011

    Article  CAS  Google Scholar 

  47. Freudenberger RS et al. (2004) Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure. Expert Opin Investig Drugs 13: 1509–1516

    Article  CAS  Google Scholar 

  48. Ezekowitz JA et al. (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107: 223–225

    Article  Google Scholar 

  49. Mancini DM et al. (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: 294–299

    Article  CAS  Google Scholar 

  50. Silverberg DS et al. (2003) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37: 1775–1780

    Article  Google Scholar 

  51. Parsa CJ et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999–1007

    Article  CAS  Google Scholar 

  52. Calvillo L et al. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802–4806

    Article  CAS  Google Scholar 

  53. Bahlmann FH et al. (2004) Erythropoietin regulates endothelial progenitor cells. Blood 103: 921–926

    Article  CAS  Google Scholar 

  54. Drexler H and Hassenfuss G (2003) Physiology of the normal and failing heart. In Cardiology, 829–844 edn 2 (Eds Crawford MH et al.) London: WJ Mosby

    Google Scholar 

  55. del Monte F et al. (2003) Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol 546: 49–61

    Article  CAS  Google Scholar 

  56. Hoshijima M et al. (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8: 864–871

    Article  CAS  Google Scholar 

  57. Schmitt JP et al. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299: 1410–1413

    Article  CAS  Google Scholar 

  58. Follath F et al. (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360: 196–202

    Article  CAS  Google Scholar 

  59. Wencker D et al. (2003) A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111: 1497–1504

    Article  CAS  Google Scholar 

  60. Limbourg FP et al. (2005) Bone marrow stem cells for myocardial infarction: effector or mediator? Circ Res 96: 6–8

    Article  CAS  Google Scholar 

  61. Menasché P et al. (2001) Myoblast transplantation for heart failure. Lancet 357: 279–280

    Article  Google Scholar 

  62. Wollert KC et al. (2005) Clinical applications of stem cells for the heart. Circ Res 96: 151–163

    Article  CAS  Google Scholar 

  63. Assmus B et al. (2004) Transcoronary transplantation of progenitor cells and recovery of left ventricular function in patients with chronic ischemic heart disease: results of a randomized, controlled trial. Circulation 110 (Suppl III): S238

    Google Scholar 

  64. Perin EC et al. (2004) Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 110 (Suppl 1): SII213–SII218

    Google Scholar 

  65. Sabbah HN et al. (2003) Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res 93: 1095–1101

    Article  CAS  Google Scholar 

  66. Mann DL et al.; Acorn Investigators and Study Coordinators (2004) Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. J Card Fail 10: 185–192

    Article  Google Scholar 

  67. Wu AH et al. (2005) Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 45: 381–387

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lecturer Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany

    Ulf Landmesser

  2. Chairman of the Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Germany

    Helmut Drexler

Authors
  1. Ulf Landmesser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helmut Drexler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helmut Drexler .

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landmesser , U., Drexler , H. Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat Rev Cardiol 2, 628–638 (2005). https://doi.org/10.1038/ncpcardio0371

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0371

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing